Kiwon Lee, MD
Vascular Neurology · Summit, NJNPI 1710908322
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,700 of the $7,379 with a category attached, or 77.3%. UCB, Inc. accounts for 77.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $3,790 and has fallen 84.3% since, to $596 in 2025.
Across 24 payments — averaging $307.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$6K
- BTG International Inc.$676
- AstraZeneca$450
- La Jolla Pharmaceutical Company$209
- Stryker$115
- Chiesi USA, Inc.$96
- plus $110 from 2 others
What the payments were for
- Consulting fees$5,70077%
- Food & beverage$1,67923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 5 | $5,722 |
| BTG International Inc. | 9 | $676 |
| AstraZeneca(2 entities) | 4 | $450 |
| La Jolla Pharmaceutical Company | 2 | $209 |
| Stryker | 1 | $115 |
| Chiesi USA, Inc. | 1 | $96 |
| Medtronic | 1 | $94 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few vascular neurology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Summit
- John HannaSummit$3K
- Kristine ArandelaSummit$22
- Inder SinghNeptune$119K
- Fred RinconCamden$85K
- Kevin CrutchfieldHackensack$19K
- Peter BarcasNeptune$10K
- Pratit PatelNeptune$3K
- Laura RisleyNeptune$3K
- Gerald FerenczToms River$2K
- Steven ShapiroLivingston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.